The original hepatitis B vaccine, manufactured in the 1980s, was the first vaccine to prevent human cancer. Liver cancer, which the hepatitis B virus can cause, is the second leading cause of cancer deaths throughout the world, and half of these are from hepatitis B.
Now, a more effective and more practical version of that vaccine is available for adults. HEPLISAV-B™ was recently licensed and recommended for use in adults 18 years of age and older. Previous hepatitis B vaccines required three doses over a six-month span. Since the new vaccine requires just two doses, public health officials hope more adults will begin and complete hepatitis B vaccination. Currently, approximately 1 of 4 U.S. adults are vaccinated against hepatitis B.
In this video, Dr. Offit talks about the vaccine technology advancements used to make the improved hepatitis B vaccines for adults. These include the advent of a new adjuvant that evokes a stronger immune response and delivers better protection.
View this video with a transcript